BRPI0413726A - combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors - Google Patents

combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors

Info

Publication number
BRPI0413726A
BRPI0413726A BRPI0413726-4A BRPI0413726A BRPI0413726A BR PI0413726 A BRPI0413726 A BR PI0413726A BR PI0413726 A BRPI0413726 A BR PI0413726A BR PI0413726 A BRPI0413726 A BR PI0413726A
Authority
BR
Brazil
Prior art keywords
reuptake inhibitors
norepinephrine
combination
serotonin
serotonin reuptake
Prior art date
Application number
BRPI0413726-4A
Other languages
Portuguese (pt)
Inventor
Megan Ann Gibbs
Earl Laux Giller Jr
Gerard Joseph Marek
Robert Clyde Marshall
Tatiana Stanislavovna Ramey
Erik Ho Fong Wong
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/769,018 external-priority patent/US20050014848A1/en
Priority claimed from US10/860,721 external-priority patent/US20050009927A1/en
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0413726A publication Critical patent/BRPI0413726A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

"COMBINAçãO DE INIBIDORES DA RECAPTAçãO DE SEROTONINA E INIBIDORES DA RECAPTAçãO DE NOREPINEFRINA". A presente invenção refere-se a uma modalidade de composições farmacêuticas e de métodos para tratamento de depressão em um mamífero. A um mamífero que necessite de tal tratamento são administrados: (i) pelo menos um inibidor de recaptação de serotonina ou um seu sal farmaceuticamente aceitável, e (ii) pelo menos um inibidor de recaptação de norepinefrina ou um seu sal farmaceuticamente aceitável, em que o inibidor de norepinefrina é selecionado do grupo constituído em Estrutura II, Estrutura III, e Estrutura IV como aqui definido."Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors". The present invention relates to one embodiment of pharmaceutical compositions and methods for treating depression in a mammal. A mammal in need of such treatment is administered: (i) at least one serotonin reuptake inhibitor or a pharmaceutically acceptable salt thereof, and (ii) at least one norepinephrine reuptake inhibitor or pharmaceutically acceptable salt thereof, wherein The norepinephrine inhibitor is selected from the group consisting of Structure II, Structure III, and Structure IV as defined herein.

BRPI0413726-4A 2003-09-09 2004-09-02 combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors BRPI0413726A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US50127503P 2003-09-09 2003-09-09
US53889804P 2004-01-23 2004-01-23
US54069604P 2004-01-30 2004-01-30
US10/769,018 US20050014848A1 (en) 2002-01-23 2004-01-30 Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
US10/860,721 US20050009927A1 (en) 2002-01-23 2004-06-03 Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
PCT/IB2004/002864 WO2005023265A1 (en) 2003-09-09 2004-09-02 Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors

Publications (1)

Publication Number Publication Date
BRPI0413726A true BRPI0413726A (en) 2006-11-07

Family

ID=34280166

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413726-4A BRPI0413726A (en) 2003-09-09 2004-09-02 combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors

Country Status (7)

Country Link
EP (1) EP1667686A1 (en)
BR (1) BRPI0413726A (en)
CA (1) CA2542339A1 (en)
MX (1) MXPA06002778A (en)
NL (1) NL1026989C2 (en)
TW (1) TW200526197A (en)
WO (1) WO2005023265A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1575590B1 (en) 2002-12-27 2007-10-24 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (en) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd COMBINATION OF CARBOSTIRILE DERIVATIVES AND INHIBITORS OF SEROTONINE REABSORTION FOR THE TREATMENT OF ANIMO DISORDERS
EP1763354A2 (en) * 2004-06-09 2007-03-21 Pfizer Limited Use of reboxetine for the treatment of pain
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232805A1 (en) * 2002-04-24 2003-12-18 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders

Also Published As

Publication number Publication date
TW200526197A (en) 2005-08-16
EP1667686A1 (en) 2006-06-14
WO2005023265A1 (en) 2005-03-17
MXPA06002778A (en) 2006-06-14
CA2542339A1 (en) 2005-03-17
NL1026989A1 (en) 2005-03-10
NL1026989C2 (en) 2006-01-10

Similar Documents

Publication Publication Date Title
BRPI0607536A2 (en) pain treatment
BRPI0413821A (en) compound or pharmaceutically acceptable salts thereof, pharmaceutical composition, gsk-3 inhibitor, and agent for treating or preventing a gsk-3 mediated disease
BR0311419A (en) Thiophene amidines, their compositions and methods for treating complement-mediated diseases and conditions
AR044007A1 (en) METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
BRPI0512220A (en) method for treating, preventing or ameliorating a disease or disorder; pharmaceutical composition; process for the preparation of a compound; and use of a compound
UY26635A1 (en) SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
BR0304648A (en) Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
BRPI0509172A (en) at least one chemical entity, pharmaceutical composition, methods for treating a patient, inhibiting at least one enzyme using atp, and treating at least one disease, use of at least one chemical entity, and method for the manufacture of a medicament
BR112012010705A2 (en) compound, pharmaceutical composition, combined pharmaceutical product, use of a compound, and methods for treating a disease or condition, and for inhibiting bromodomain
BR112012026948A2 (en) compound, pharmaceutical composition, and methods for improving bone metabolism, for preventing or treating a disease associated with bone metabolism, and for preventing or treating osteoporosis.
BRPI0314308B8 (en) opioid antagonists, their uses, and pharmaceutical composition
KR980000447A (en) Pharmaceutical composition consisting of mirtazapine and one or more selective serotonin reuse inhibitors
BRPI0512213A (en) method for treating, preventing or ameliorating a disease or disorder; pharmaceutical composition; process for the preparation of a compound; and use of a compound
AR060089A1 (en) PAIN TREATMENT
BR0200155A (en) Combined treatment for depression
AR067495A1 (en) PHARMACEUTICAL COMPOSITIONS AND PROCEDURE DRY EYE DISORDER TREATMENTS
BRPI0508254A (en) methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
BR0314699A (en) Compound, composition and methods for treating pain and inhibiting vr1 function in a cell
BRPI0413580A (en) compound, pharmaceutical composition, and methods for treating or preventing cancer in a mammal in need of such treatment, for modulating mitotic spindle formation and for inhibiting mitotic kinesin ksp
BRPI0511722A (en) 3-amino-1-arylpropylindoles as monoamine reuptake inhibitors
BRPI0507657A (en) compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, method for treating a disorder, and use of a compound or a pharmaceutically acceptable salt thereof
EA200702282A1 (en) COMBINATION OF FERROHIN AND DERIVATIVE ARTEMIZININ FOR THE TREATMENT OF MALARIA
DK1370260T3 (en) Azoles as malonyl-coa-decarboxylase inhibitors useful as metabolic modulators
BR112023023030A2 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION
BRPI0410222A (en) treatment of bipolar disorders and associated symptoms

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.